Observational study finds increased risk of preterm birth in GLP-1 drug users — Evidence Review
Published in Human Reproduction Open, by researchers from Copenhagen University Hospital Hvidovre
Researched by
— the AI search engine for science
Table of Contents
A large Danish study found that accidental use of GLP-1 medications (such as Ozempic and Wegovy) in early pregnancy was only linked to a higher risk of premature birth when prescribed for diabetes, not for weight loss. Most recent research generally supports these findings, highlighting the underlying role of diabetes as a risk factor rather than the medications themselves; details are available in the published study.
- Recent cohort and meta-analytic studies consistently find no significant increase in major birth defects or pregnancy losses from GLP-1 receptor agonist exposure in early pregnancy, and emphasize that underlying maternal conditions like diabetes are more important determinants of risk 2 6 7 8.
- Some evidence suggests GLP-1 drugs may be linked to increased risks (e.g., preterm birth, gestational diabetes, hypertensive disorders), but these risks often diminish or disappear after adjusting for confounders such as diabetes status and maternal obesity 4 5 7.
- Animal and limited human data have previously driven caution about GLP-1 use in pregnancy due to potential adverse effects, but recent real-world human studies are providing cautious reassurance, especially regarding inadvertent early pregnancy exposure outside of diabetes treatment contexts 1 6 7.
Study Overview and Key Findings
As GLP-1 receptor agonists (GLP-1 RAs) like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) become increasingly popular for diabetes and weight management, questions about their safety in pregnancy have grown more urgent. The rapid rise in prescriptions means accidental early pregnancy exposure is increasingly common—a scenario for which clinical guidance has been lacking. This large Danish study is notable for its size and its nuanced approach: it distinguishes between women taking GLP-1 RAs for diabetes versus weight loss, revealing key differences in pregnancy risks based on indication. Unlike many earlier studies or guidelines, it accounts for multiple confounding factors and leverages comprehensive national registry data.
| Property | Value |
|---|---|
| Study Year | 2023 |
| Organization | Copenhagen University Hospital Hvidovre |
| Journal Name | Human Reproduction Open |
| Authors | Henriette Svarre Nielsen, Kathrine Hviid |
| Population | Women with pregnancies involving GLP-1 medications |
| Sample Size | n=756,636 |
| Methods | Observational Study |
| Outcome | Preterm birth, pre-eclampsia, gestational diabetes, stillbirth |
| Results | Increased risk of premature birth for diabetes users of GLP-1 drugs |
Literature Review: Related Studies
To situate these findings in the broader scientific context, we searched the Consensus database, which contains over 200 million research papers. The following search queries were used:
- Ozempic Wegovy pregnancy outcomes
- GLP-1 drugs premature birth risk
- diabetes medications pregnancy complications
Below is a summary of key topics and findings from recent studies:
| Topic | Key Findings |
|---|---|
| Are GLP-1 receptor agonists associated with pregnancy complications or congenital defects? | - Most meta-analyses and cohort studies find no significant increase in major congenital malformations or pregnancy losses with GLP-1 RA exposure in early pregnancy 2 6 7 8. - Some animal studies show adverse effects, but human studies are more reassuring 1 7 8. |
| How do underlying maternal conditions (e.g., diabetes, obesity) influence pregnancy risks? | - Diabetes itself is a strong driver of adverse pregnancy outcomes, and adjusting for diabetes often removes apparent risks from GLP-1 RAs 2 4 7 8 12. - Obesity and maternal metabolic status significantly shape pregnancy risk profiles 4 5 12. |
| What is the evidence for stopping or continuing GLP-1 drugs prior to conception? | - Current guidelines recommend stopping GLP-1 RAs before pregnancy, but recommendations are based on limited human data; recent studies provide cautious reassurance for inadvertent early exposure 1 2 6 7 12. - Some data suggest preconception use may reduce certain risks, but evidence is not definitive 5. |
| What are the comparative risks of other antidiabetic medications (e.g., metformin, insulin) in pregnancy? | - Metformin is generally considered safe and effective for gestational diabetes, with no major short-term adverse outcomes 9 10 11. - Second-line antidiabetic agents, including GLP-1 RAs, do not appear to increase major malformation risk compared to insulin 8. |
Are GLP-1 receptor agonists associated with pregnancy complications or congenital defects?
Much of the recent literature finds no consistent association between GLP-1 RA exposure in early pregnancy and major adverse outcomes such as congenital anomalies or pregnancy loss. While animal studies and early theoretical concerns prompted caution, large human cohort studies and meta-analyses increasingly report neutral or cautiously reassuring results, especially when controlling for maternal comorbidities like diabetes and obesity 2 6 7 8.
- Multiple meta-analyses and cohort studies report no statistically significant increase in major congenital malformations, cardiac malformations, or pregnancy loss with GLP-1 exposure 2 6 7 8.
- Animal studies showed reduced fetal growth and skeletal changes, but these findings have not been mirrored in most human studies 1 7.
- A large meta-analysis found a possible small elevated risk for renal malformations, but this was likely driven by confounding factors in a single cohort 7.
- The new Danish study’s finding—that increased preterm birth risk is confined to women with diabetes—aligns with the overall trend of neutral findings once underlying maternal health is accounted for 2 6 7.
How do underlying maternal conditions (e.g., diabetes, obesity) influence pregnancy risks?
The literature robustly supports the conclusion that underlying maternal health, particularly diabetes and obesity, is a primary determinant of adverse pregnancy outcomes. Studies that control for these factors often find that differences attributed to GLP-1 RAs disappear, indicating that metabolic disease, rather than medication exposure, is the main risk factor 4 5 7 8 12.
- Diabetes and obesity increase the risk of preterm birth, gestational diabetes, and hypertensive disorders, independent of specific medication exposures 4 12.
- Studies adjusting for diabetes and obesity status typically find no significant difference in pregnancy outcomes between GLP-1 RA-exposed and unexposed groups 2 7 8.
- The current study’s distinction between diabetes and weight loss indications for GLP-1 RAs is echoed in other research emphasizing the need for individualized risk assessment 12.
- Some studies find that preconception GLP-1 use may reduce obstetric risk, but more research is needed 5.
What is the evidence for stopping or continuing GLP-1 drugs prior to conception?
Guidelines continue to recommend stopping GLP-1 RAs before planned pregnancy, largely based on animal data and theoretical concerns. However, recent human studies—including the new Danish cohort—add nuance, suggesting that unintentional early exposure may not pose major risks outside the context of diabetes 1 2 6 7 12. Evidence for benefits or harms of preconception use remains limited and sometimes contradictory.
- Systematic reviews and recent cohort studies offer cautious reassurance regarding inadvertent early pregnancy exposure, especially among women without diabetes 2 6 7.
- Guidelines still advise discontinuation before conception due to limited data and because animal studies showed adverse effects 1 12.
- Some studies suggest potential benefits of preconception GLP-1 use (e.g., reduced risk of gestational diabetes or hypertensive disorders), but these findings require further validation 5.
- The new study’s finding that diabetes, not the drug, is the main risk factor, suggests future guidelines may eventually be stratified by indication and maternal risk profile 12.
What are the comparative risks of other antidiabetic medications (e.g., metformin, insulin) in pregnancy?
Metformin, another common antidiabetic, is generally found to be safe and effective for gestational diabetes, with no major short-term adverse outcomes and some potential neonatal benefits. Second-line agents, including GLP-1 RAs, have not been shown to substantially increase the risk of congenital malformations compared to insulin 8 9 10 11.
- Meta-analyses and RCTs consistently report no major increase in adverse outcomes with metformin compared to insulin 9 10 11.
- GLP-1 RAs, when compared to insulin, do not show a large increased risk of major congenital malformations in early pregnancy 8.
- The focus of recent guidelines is on optimizing glycemia and metabolic health prior to conception, regardless of the specific medication 12.
- The new Danish study supports the view that medication choice is less important than underlying disease control for risk assessment 2 4 12.
Future Research Questions
Although the Danish study and recent literature have advanced understanding, significant questions remain regarding the safety and optimal management of GLP-1 RA exposure in pregnancy. Further research is needed to clarify risks, understand mechanisms, and guide individualized counseling, especially as the use of these medications expands among reproductive-age women.
| Research Question | Relevance |
|---|---|
| Does GLP-1 receptor agonist exposure in early pregnancy affect long-term child development? | Long-term data on neurodevelopmental, metabolic, and growth outcomes in children exposed to GLP-1 RAs in utero are lacking, and most current studies focus on perinatal outcomes 1 6 7. |
| How does the indication for GLP-1 RA use (diabetes vs weight loss) alter pregnancy risks? | The new study suggests differing risks based on prescription reason; clarifying this distinction could improve risk stratification and counseling for women who become pregnant while taking these medications 2 4 12. |
| What is the optimal preconception discontinuation period for GLP-1 receptor agonists? | Current recommendations are based on limited animal data; real-world studies are needed to determine the safest and most practical discontinuation window prior to conception 1 12. |
| Are there specific maternal or fetal subgroups at higher risk from GLP-1 exposure? | Identifying genetic, metabolic, or other risk factors could refine counseling and allow for more personalized guidance; current studies rarely stratify by such subgroups 2 7 12. |
| How do GLP-1 receptor agonists compare with other antidiabetic medications in terms of pregnancy outcomes? | Direct head-to-head comparisons with metformin, insulin, or SGLT2 inhibitors could inform medication choices for women of childbearing age, especially as GLP-1 RAs become more widely used 8 9 10 11 12. |